Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersBrief Reviews
You have accessRestricted Access

Chemokines in Renal Injury

Arthur C. K. Chung and Hui Y. Lan
JASN May 2011, 22 (5) 802-809; DOI: https://doi.org/10.1681/ASN.2010050510
Arthur C. K. Chung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Y. Lan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

The main function of chemokines is to guide inflammatory cells in their migration to sites of inflammation. During the last 2 decades, an expanding number of chemokines and their receptors have driven broad inquiry into how inflammatory cells are recruited in a variety of diseases. Although this review focuses on chemokines and their receptors in renal injury, proinflammatory IL-17, TGFβ, and TWEAK signaling pathways also play a critical role in their expression. Recent studies in transgenic mice as well as blockade of chemokine signaling by neutralizing ligands or receptor antagonists now allow direct interrogation of chemokine action. The emerging role of regulatory T cells and Th17 cells during renal injury also forges tight relationships between chemokines and T cell infiltration in the development of kidney disease. As chemokine receptor blockade inches toward clinical use, the field remains an attractive area with potential for unexpected opportunity in the future.

Renal inflammation underlies many chronic kidney diseases and the infiltration of leukocytes mediates much of the nephritogenic inflammatory response. As several recent reviews have dealt with the basic biology, mouse models, and blockade studies of chemokines in renal diseases,1–11 we focus here on recent developments in pathophysiology of that chemokine effect.

CHEMOKINES AND CHEMOKINE RECEPTORS

Chemokines are a group of chemotactic cytokines (approximately 8 to 17 kD) with the ability to bind G-protein–coupled receptors and act as potent attractants for leukocytes in acute and chronic inflammation. There are four subfamilies of chemokines, including CCL, CXCL, CX3CL, and CL (Figure 1).7,6 At present, 19 receptors are known (Figure 1).6,7 The large CC chemokine family has the first two cysteine residues adjacent to each other, whereas the CXC family has a single amino acid residue in between the first two cysteines. Fractalkine (CX3CL1) is the only member of the CX3C chemokine family where three amino acid residues separate the first two cysteines. Finally, two related chemokines absent the two cysteine residues that bind the XCR1 receptor belong to the XC family. As shown in Figure 1, many chemokines bind multiple receptors and most receptors bind multiple chemokines. However, CC chemokine receptors exclusively bind CC chemokines and CXC receptors bind only CXC chemokines.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Chemokines and their receptors. Four subfamilies of chemokines have been characterized, including the CC subfamily, the CXC subfamily, the XC subfamily, and the CX subfamily.

Chemokines and their corresponding receptors are expressed in different cell types (Figure 2).7,12 Generally speaking, monocytes are mostly attracted by CCL chemokines acting through CCR1, CCR2, and CCR5 receptors, whereas neutrophils are the target of CXCL chemokines through CXCR1 and CXCR2 receptors (Figure 2). Inflammatory cells such as T-helper1 (Th1) cells and natural killer cells are attracted by chemokines binding to CXCR3, CXCR6, CCR5, and CX3CR1 to induce local type 1 cytokine (IL-2, INF-γ)–mediated inflammatory responses, whereas Th2 cells and eosinophils are recruited by ligands for CCR3, CCR4, and CCR8 during a type 2 cytokine (IL-4, IL-5, and IL-13)-mediated inflammatory responses. CCR6 and CXCR3 receptors are detected on Th17 cells and a spectrum of chemokines receptors are expressed in regulatory T cells (Tregs), such as CCR4–8, CXCR3, and CXCR6. In kidneys, endothelial cells, podocytes, mesangial cells (MCs), tubular epithelial cells, and interstitial fibroblasts can also produce inflammatory chemokines upon stimulation.3,9

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Interaction of chemokines and receptors on leukocyte subsets during acute and chronic kidney injury. Kidney diseases are characterized by the accumulation of various leukocyte subsets that are controlled by chemokines through their corresponding receptors expressed by the different subsets. Although infiltration of neutrophils and monocytes mediate acute kidney injury, activation of T cells, macrophages, and dendritic cells promote progression of chronic kidney disease.

REGULATION OF CHEMOKINE EXPRESSION

On the basis of their regulation and production, chemokines can be classified broadly as homeostatic/lymphoid or inflammatory chemokines. The former is responsible for leukocyte homing and lymphocyte recirculation under normal conditions, whereas the inflammatory chemokines contribute to progression of inflammatory diseases.7

In the normal kidney, production of inflammatory chemokines is low, but is significantly increased under pathophysiological circumstances such as ischemia, toxin exposure, or acute inflammation.3 Proinflammatory cytokines, such as TNF-α and IL-1β, and reactive oxygen species are major mediators responsible for chemokine expression3,7 through the NF-κB pathway,13 including connective tissue growth factor-stimulated NF-κB.14 Inflammatory chemokines are also induced by other mediators, including cyclic adenosine monophosphate, growth factors such as PDGF, basic fibroblast growth factors, pathogen-associated molecules such as lipopolysaccharides, Ig aggregates, LDL, IFN-γ, and vasoactive substances like angiotensin II, or under diabetic conditions.7,15 Activation of TGFβ/Smad2,3 signaling during renal inflammation also produces a chemotatic effect on macrophages by inducing monocyte chemoattractant protein-1 (MCP-1)/CCL2 expression.16,17

Furthermore, urinary levels of TWEAK, a cytokine of the TNF superfamily, significantly increase and correlate with the activity of renal disease in patients with active lupus nephritis.18 Exposure to TWEAK also induces MCP-1/CCL2, RANTES/CCL5, MIP-1α/CXCL2, intraperitoneally-10/CXCL10, and SLC/CCL21 in MCs or tubular epithelial cells through a noncanonical NF-κB pathway, thereby promoting leukocyte recruitment to the kidney during injury.19,18,20

The IL-17/IL-23 signaling pathway through Th17 cells also regulates the production of Th1-attracting chemokines and inflammatory cell infiltration. In mouse MCs, IL-17 enhances the production of MCP-1/CCL2, MIP-1α/CCL3, LARC/CCL20, and MIP-2/CXCL2 through the MAPK pathways (p38 MAPK and ERK1/2) to recruit T cells and monocytes.21–23 Mice infused with Th17 cells also develop albuminuria, which is associated with higher levels of renal GRO-α/CXCL1 and neutrophils in glomeruli.24

ROLE OF CHEMOKINES IN ACUTE KIDNEY INJURY

Rapid accumulation of neutrophils and monocyte/macrophages in injured kidney is an essential feature of the innate immune response induced by ischemia-reperfusion injury (IRI).25 Several chemokine families show a strong relationship to acute kidney injury (AKI), including the CXCL subfamily—IL-8/CXCL8, Gro-α/CXCL1, and MIP-2/Gro-β/CXCL2—that act primarily on neutrophils (Figure 2), the CCL subfamily (MCP-1/CCL2), the CX3CL subfamily (fractalkine/CX3CL1) that have specific effects on monocytes and monocyte-derived lineages, and RANTES/CCL5 that operate more broadly to attract cells monocytes and lymphocytes (Figure 2).10

Role of the CXCL Family in Innate Immune Responses in AKI

After IRI, an increase in the expression of IL-8/CXCL8 and Gro-α/CXCL1 associates with marked neutrophil infiltration,26,27 suggesting that CXCL chemokines play a significant role in neutrophil recruitment. The ability of IL-8/CXCL8 to recruit neutrophils by upregulating tubular ICAM-1, by engaging their cognate receptor, CXCR-1, to activate the p38 MAPK signaling pathway reveals an essential role of the CXCL family in the process of neutrophil recruitment.28

The functional role of CXCL family in AKI is clearly demonstrated by finding that treatment with a CXCR2 inhibitor or neutralizing antibodies to Gro-α/CXCL1 or MIP-2/Gro-β/CXCL2 during renal IRI blocks interstitial neutrophil infiltration, reduces renal damage, and improves survival.27,26 Deficiency of IL-23, IL-17A, or IL-17 receptor, or the addition of neutralizing antibodies to CXCR2 in mice, attenuates neutrophil infiltration in IRI.29,30 During the innate immune response in IRI, neutrophils produce a large amount of IL-17A, which in turn induces proinflammatory cytokines and chemokine (CXCL1/2) to promote kidney inflammation. It is known that IL-17 is able to strongly repress TNF-α–stimulated expression of intraperitoneally-10/CXCL10, I-TAC/CXCL11, and RANTES/CCL5, but it also acts synergistically with TNF-α to induce IL-8/CXCL8, Gro-α/CXCL1, and MIP-3α/CCL20.31 Thus, in addition to proinflammatory cytokines, IL-17 and IL-23 signal pathways are new modulators of chemokine-mediated neutrophil infiltration during the innate immune response to IRI, and targeting this pathway may be a new approach for its treatment.

Recent studies also reveal a role for CXCR3 in IRI in mice. CXCR3 is mainly expressed on activated Th1 cells to mediate Th1 recruitment.32 CXCR3 ligands (intraperitoneally-10/CXCL10 and Mig/CXCL9) are upregulated in postischemic tissue and CXCR3-deficient kidneys with IRI decrease their infiltration of IFN-γ–producing CD4+ T cells as well as the severity of acute tubular necrosis.33 This protective effect is abrogated by adoptive transfer of wild type CD3+ cells into CXCR3 null mice,33 demonstrating a critical role for CXCR3 in Th1 cell recruitment to the ischemic kidney. Furthermore, administration of IL-13, a potent Th2 cytokine, also exhibits an inhibitory effect on interstitial infiltration by neutrophils and macrophages, which associates with reduced expression of MIP-2/Gro-β/CXCL2, IL-8/CXCL8, and MCP-1/CCL2,34 supporting the involvement of CXCL chemokines in the T cell infiltration of AKI.

Role of CCL and CXC3L Families in AKI

Presently, it is known that macrophages in the inflamed kidney are either recruited from the circulation or derived from the proliferation of resident monocytes. MCP-1/CCL2, RANTES/CCL5, MIP-1α/CCL3, and MIP-1β/CCL4 are the most commonly described chemokines used in the recruitment of monocyte/macrophages during renal inflammation.11,35 The corresponding receptors mediate firm adhesion (CCR1), shape change (CCR2 and CCR5), spreading (CCR2 and CCR5), and transmigration.11

A critical role for chemokine signaling in macrophage infiltration is demonstrated by a number of functional blocking experiments. For example, abrogation of CCR1 or CCR2 signaling in a mouse model of AKI results in reduction of interstitial macrophage infiltrates.36,37 Delivery of a truncated MCP-1/CCL2 protein into mice with IRI also blocks activation of CCR2, thereby inhibiting macrophage infiltration.38,39 Interestingly, injured kidneys from mice lacking CCR1 also reduce expression of CCR1 ligands (MIP-1α/CCL3 and RANTES/CCL5), suggesting the existence of a positive feedback loop for chemokine production.36,37

Several recent reports highlight the protective role of Tregs during IRI.40–43 However, the source of the renal Tregs in response to IRI is uncertain. As renal expression of MCP-1/CCL-2 is greatly elevated after IRI and CCR2 has been shown to guide Tregs toward arthritic joints, CCL chemokines may function to regulate Treg cell accumulation in acute kidney injury.44,36,45

Dendritic cells (DCs) are also an important link between innate and adaptive immunity and their role in renal injury is well known.46 After IRI, renal DCs produce both the proinflammatory cytokines (TNF-α, IL-6, and CCL) and chemokines (MCP-1/CCL2 and RANTES/CCL5).47 Thus, secretion of these CCL chemokines from DCs may attract monocyte/macrophage to the site of inflammation.

Increased fractalkine/CX3CL1 expression in injured endothelial cells and blood vessels is also observed in AKI.48,49 CX3CR1 is predominantly expressed on macrophages and blockade of CX3CR1 by neutralizing antibody or gene inactivation protects the kidney from ischemic injury by inhibiting macrophage infiltration, suggesting that fractalkine/CX3CL1is a potent chemoattractant molecule for macrophages carrying CX3CR1.48,49 CCR2 and CX3CR1 are both essential for the acute release of macrophages from the bone marrow for infiltration into injured kidney.50 Although ablation of CCR2 and CX3CR1 diminishes macrophage infiltration, MCP-1/CCL2 deficiency exerts no effect on renal macrophage infiltration, suggesting the presence of ligand redundancy. Thus, targeting the early macrophage trafficking by CCR2 and CXC3R1 may have therapeutic potential for AKI.

ROLE OF CHEMOKINES IN CHRONIC KIDNEY DISEASES

Accumulating data from clinical studies and animal models support the notion that chemokines and their cognate receptors play a critical role in the recruitment of T cells, macrophages, and dendritic cells during the development of chronic renal injury (Figure 2).10 Although levels of urinary IL-8/CXCL8 excretion are increased in patients in the acute phase of various forms of glomerulonephritis, a large number of CXCR1-positive neutrophils are also found in both glomeruli and the tubulointerstitium of the patients with membranous proliferative glomerulonephritis, lupus nephritis, and crescentic glomerulonephritis.51,11 The functional role of CXCL family in inflammatory kidney disease is clearly demonstrated by the finding that administration of an anti-IL-8/CXCL8 antibody to rabbits with an immune complex nephritis reduces proteinuria and neutrophil recruitment.52

Role of CCL and CX3CL Chemokines in Chronic Kidney Disease

Increasing evidence suggests a switch of expression of CXCL chemokines (IL-8/CXCL8) to CCL chemokines (MCP-1/CCL2, RANTES/CCL5) in the transition from acute to chronic inflammation (Figure 2).53 As in AKI, urinary IL-8/CXCL8 levels are increased early, but elevated urinary MCP-1 levels associate with progressive renal injury.54,55 In addition, enhanced expression of glomerular MCP-1/CCL2 and ligands of CCR5 (including RANTES/CCL5, MIP-1α/CCL3, and MIP-1ß/CCL4) are detected in patients with various forms of glomerulonephritis.56–60

Increased levels of MCP-1/CCL2 are also associated with progressive tubulointerstitial disease as tubular epithelial cells are rich sources of CCL chemokines, including MCP-1/CCL2, RANTES/CCL5, and MIP-1α/CCL3.55,61,9 In unilateral ureteral obstruction (UUO) producing fibrosis, upregulation of tubulointerstitial MCP-1/CCL2 correlates with degree of macrophage infiltration, which is associated with activation of the TGFβ/Smad3 signaling pathway.16,17 TGFβ signals through its downstream mediator, Smad3, to induce MCP-1 expression. Thus, mice deficient in Smad7, an inhibitor of TGFβ/Smad signaling, results in enhanced TGFβ/Smad3 signaling through which MCP-1/CCL2–dependent macrophage infiltration and tubulointerstitial fibrosis develop in the UUO kidney.16 In contrast, inhibition or loss of TGFβ/Smad3 signaling blocks MCP-1 expression and macrophage accumulation in anti-GBM nephritis and UUO.17,62–65 Thus, upregulation of MCP-1/CCL2 and the development of macrophage accumulation in chronic kidney disease may be TGFβ/Smad3–dependent.

A critical role for CCL chemokines in progressive renal injury is suggested by functional blocking studies, including treatment with neutralizing antibodies to CCL chemokines (MCP-1/CCL2) or their receptors (CCR2), chemically modified chemokines (RANTES/CCL5), truncated chemokines (MCP-1/CCL2), or small-molecule receptor antagonists.10,2,1,66–74 All of these studies confirm that blockade of chemokines results in a suppressive effect on glomerular leukocyte infiltration, proteinuria, and crescent formation in rodent models of glomerulonephritis, tubulointerstitial macrophage infiltration, and development of diabetic nephropathy.66–74 Furthermore, in type I and type II diabetic mouse models, deficiency of MCP-1/CCL2 not only ameliorates renal function but also reduces macrophage infiltration as well as renal fibrosis.75,76

Like AKI, fractalkine/CX3CL1 is also detected in renal biopsies from patients with progressive kidney injury.77–79 Fractalkine/CX3CL1 and its receptor CX3CR are upregulated during renal injury in several mouse models, including experimental folic acid nephropathy, crescentic GN, and diabetic nephropathy.80,81,78,82,83,77,9 Treatment with a neutralizing antibody against fractalkine/CX3CL1 improves renal damage by blocking crescentic formation and macrophage infiltration in rat nephrotoxic nephritis.84 All these studies imply there might be an important role for CCL and CX3CL chemokines in chronic renal disease regardless of inciting events.

Role of Chemokines in T Cell Infiltration during Kidney Injury

Increasing evidence also suggests the functional importance of chemokines and their receptors in the recruitment of T cells into the kidney with chronic kidney disease (Figure 2).85,86 MIP-1α/CCL3 is elevated in the urine and in the crescentic lesion in patients with crescentic glomerulonephritis, whereas its cognate receptors, CCR1 and CCR5, are expressed in CD3+ T cells and CD68+ macrophages infiltrating glomeruli and the interstitium.55,87 In a mouse model of crescentic glomerulonephritis, upregulation of renal CCR5 ligands (MIP-1α/CCL3, MIP-1β/CCL4, and RANTES/CCL5) correlates with the recruitment of monocytes and T cells,88,35 suggesting a close link between the CCL chemokines and cell-mediated immune responses. This notion is further confirmed by finding that CCR5 null mice have an increased renal Th1 response.88 Because the CCR5 ligands (MIP-1α/CCL3 and RANTES/CCL5) also act through CCR1, blockade of CCR1 with the pharmacologic CCR1 antagonist, BX471, significantly reduces renal chemokine expression, T cell infiltration, and glomerular crescent formation in CCR5 null mice, indicating that increased renal leukocyte recruitment and subsequent tissue damage in nephritic mice depend on functional CCR1.88 Thus, CCR5 deficiency aggravates glomerulonephritis through enhanced CCL3/CCL5-CCR1–driven recruitment of T cells and macrophages to the kidney.35 On the other hand, abrogation of Th1 signaling by deleting the T-bet gene, a transcription factor for Th1 cells, not only attenuates glomerular crescent formation and accumulation of CD4+ T cells and macrophages, but it also reduces intrarenal expression of RANTES/CCL5, Mig/CXCL9, and CXCR3.89 However, injection of Th1 cells in mice increases renal expression of MCP1/CCL2 and RANTES/CCL5, and causes progressive albuminuria along with crescent formation.24 Taken together, CCL chemokines participate in activating infiltrating cells related to Th1 immune responses during inflammatory renal injury.

Furthermore, CXCR3, which is highly expressed on Th1 CD4+ cells, is also responsible for the trafficking of Th1 cells into injured tissues because its expression correlates with elevated levels of urinary CXCR3+, CD4+ T cells, and upregulation of its ligand, intraperitoneally-10/CXCL10, in mouse models of systemic lupus erythematosus and anti–Thy-1 glomerulonephritis.90–92,9 CXCR3 deficiency reduces glomerular damage and T cell recruitment in crescentic glomerulonephritis and lupus.93,94 Most importantly, the decrease in T cell recruitment is due to reduction of both renal IFN-γ–producing Th1 cells and IL-17–producing Th17 cells.93 As CXCR3 is expressed on the Th17 cells, reduction of Th17 cell infiltration may be related to impaired trafficking of these cells in CXCR3 null mice, rather than reduction of these cells within injured kidneys.93 As CXCR3 is a trafficking receptor for both Th1 and Th17 cells, CXCR3 is one of the potential targets for therapy of T cell–mediated renal injury.

During inflammatory kidney injury, chemokines and their receptors also demonstrate a strong relationship with Tregs. As Tregs have anti-inflammatory properties, their presence is protective to renal injury.95–97 Tregs suppress production of MIP-1α/CCL3 by macrophages, which in turn protects against macrophage-dependent, lymphocyte-independent injury.95 Studies from CCR7 null mice demonstrate that CCR7 on Tregs is critical for homing of Tregs to lymphoid organs and guiding the Tregs to sites of antigen-specific activation.98–100 Importantly, adoptive transfer of CCR7+ Tregs, but not CCR7- Tregs, into CCR7 null mice restores Treg numbers in lymphoid organs and ameliorates disease.100 Finally, a recent study in a mouse model of nephrotoxic nephritis shows that CCR6 is expressed on renal FoxP3+, CD4+ (Tregs), and IL-17–producing CD4+ (Th17) cells, but not on IFN-γ–producing Th1 cells.101 Upregulation of the CCR6 ligand, CCL20, also contributes to T cell recruitment, renal tissue injury, albuminuria, and loss of renal function. In contrast, deletion of CCR6 exaggerates renal injury and increases mortality among nephritic mice because of a reduction in infiltrating Tregs and Th17 cells with no affect on recruitment of Th1 cells.101 Furthermore, adoptive transfer of CCR6+ Tregs improves morphologic and functional renal injury, whereas transfer of Tregs from CCR6 null mice does not.101 These findings suggest that CCR6 mediates renal recruitment of both Tregs and Th17 cells and that the reduction of anti-inflammatory Tregs in the presence of a fully functional Th1 response aggravates renal progression in experimental glomerulonephritis.

In conclusion, results from human and experimental studies suggest that more than a single T cell subset is involved in renal injury.102 Understanding chemokine actions on cross-regulation of cell infiltration between Th1, Th17, and Treg cells should enable us to identify new therapeutic targets to treat renal injury.

CONCLUSION

In summary, evidence from experimental and clinical studies clearly demonstrates that chemokines are important regulators of leukocyte recruitment during kidney injury. Although interference with chemokine action holds great promises for the treatment of inflammatory renal diseases in experimental models, the chemotactic actions of chemokines in both initiation and progression of kidney diseases are much more promiscuous and complicated than we thought.1,2 Thus, much effort is required to further understand the mechanisms of chemokine function to develop innovative antichemokine therapies for human renal disease.

DISCLOSURES

None.

Acknowledgments

This work is supported by grants from Research Grant Council of Hong Kong (RGC GRF 768207 and 767508, CUHK5/CRF/09 to H.Y.L., 464010, 763908 and 764109 to A.C.C.) and the Chinese University of Hong Kong Direct Grants (2041507 to H.Y.L. and 2041503 to A.C.C.).

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • Copyright © 2011 by the American Society of Nephrology

REFERENCES

  1. 1.↵
    1. Anders HJ,
    2. Sayyed SA,
    3. Vielhauer V
    : Questions about chemokine and chemokine receptor antagonism in renal inflammation. Nephron Exp Nephrol 114: e33–e38, 2010
    OpenUrlPubMed
  2. 2.↵
    1. Vielhauer V,
    2. Eis V,
    3. Schlondorff D,
    4. Anders HJ
    : Identifying chemokines as therapeutic targets in renal disease: Lessons from antagonist studies and knockout mice. Kidney Blood Press Res 27: 226–238, 2004
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Segerer S,
    2. Nelson PJ,
    3. Schlondorff D
    : Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11: 152–176, 2000
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Ruster C,
    2. Wolf G
    : The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 13: 944–955, 2008
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Panzer U,
    2. Steinmetz OM,
    3. Stahl RA,
    4. Wolf G
    : Kidney diseases and chemokines. Curr Drug Targets 7: 65–80, 2006
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lazennec G,
    2. Richmond A
    : Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol Med 16: 133–144, 2010
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Galliera E,
    2. Corsi MM,
    3. Bonecchi R,
    4. Locati M,
    5. Mantovani A
    : Chemokines as pharmacological targets. Mini Rev Med Chem 8: 638–646, 2008
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Vielhauer V,
    2. Anders HJ
    : Chemokines and chemokine receptors as therapeutic targets in chronic kidney disease. Front Biosci (Schol Ed) 1: 1–12, 2009
    OpenUrlPubMed
  9. 9.↵
    1. Segerer S,
    2. Alpers CE
    : Chemokines and chemokine receptors in renal pathology. Curr Opin Nephrol Hypertens 12: 243–249, 2003
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Holdsworth SR,
    2. Tipping PG
    : Leukocytes in glomerular injury. Semin Immunopathol 29: 355–374, 2007
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Segerer S,
    2. Schlondorff D
    : Role of chemokines for the localization of leukocyte subsets in the kidney. Semin Nephrol 27: 260–274, 2007
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Lukacs-Kornek V,
    2. Engel D,
    3. Tacke F,
    4. Kurts C
    : The role of chemokines and their receptors in dendritic cell biology. Front Biosci 13: 2238–2252, 2008
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Sanz AB,
    2. Sanchez-Nino MD,
    3. Ramos AM,
    4. Moreno JA,
    5. Santamaria B,
    6. Ruiz-Ortega M,
    7. Egido J,
    8. Ortiz A
    : NF-{kappa}B in Renal Inflammation. J Am Soc Nephrol 21: 1254–1262, 2010
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Sanchez-Lopez E,
    2. Rayego S,
    3. Rodrigues-Diez R,
    4. Rodriguez JS,
    5. Rodriguez-Vita J,
    6. Carvajal G,
    7. Aroeira LS,
    8. Selgas R,
    9. Mezzano SA,
    10. Ortiz A,
    11. Egido J,
    12. Ruiz-Ortega M
    : CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. J Am Soc Nephrol 20: 1513–1526, 2009
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Tang SC,
    2. Leung JC,
    3. Chan LY,
    4. Tsang AW,
    5. Lai KN
    : Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. J Am Soc Nephrol 17: 1633–1643, 2006
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Chung AC,
    2. Huang XR,
    3. Zhou L,
    4. Heuchel R,
    5. Lai KN,
    6. Lan HY
    : Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 24: 1443–1454, 2009
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Huang XR,
    2. Chung AC,
    3. Zhou L,
    4. Wang XJ,
    5. Lan HY
    : Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 19: 233–242, 2008
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Gao HX,
    2. Campbell SR,
    3. Burkly LC,
    4. Jakubowski A,
    5. Jarchum I,
    6. Banas B,
    7. Saleem MA,
    8. Mathieson PW,
    9. Berman JW,
    10. Michaelson JS,
    11. Putterman C
    : TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 46: 24–35, 2009
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Ortiz A,
    2. Sanz AB,
    3. Munoz Garcia B,
    4. Moreno JA,
    5. Sanchez Nino MD,
    6. Martin-Ventura JL,
    7. Egido J,
    8. Blanco-Colio LM
    : Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 20: 251–258, 2009
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Sanz AB,
    2. Sanchez-Nino MD,
    3. Izquierdo MC,
    4. Jakubowski A,
    5. Justo P,
    6. Blanco-Colio LM,
    7. Ruiz-Ortega M,
    8. Selgas R,
    9. Egido J,
    10. Ortiz A
    : TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One 5: e8955, 2010
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Paust HJ,
    2. Turner JE,
    3. Steinmetz OM,
    4. Peters A,
    5. Heymann F,
    6. Holscher C,
    7. Wolf G,
    8. Kurts C,
    9. Mittrucker HW,
    10. Stahl RA,
    11. Panzer U
    : The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol 20: 969–979, 2009
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Ooi JD,
    2. Phoon RK,
    3. Holdsworth SR,
    4. Kitching AR
    : IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol 20: 980–989, 2009
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Iyoda M,
    2. Shibata T,
    3. Kawaguchi M,
    4. Hizawa N,
    5. Yamaoka T,
    6. Kokubu F,
    7. Akizawa T
    : IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: Synergy with TNF-alpha and IL-1beta. Am J Physiol Renal Physiol 298: F779–F787, 2010
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Summers SA,
    2. Steinmetz OM,
    3. Li M,
    4. Kausman JY,
    5. Semple T,
    6. Edgtton KL,
    7. Borza DB,
    8. Braley H,
    9. Holdsworth SR,
    10. Kitching AR
    : Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol 20: 2518–2524, 2009
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Furuichi K,
    2. Kaneko S,
    3. Wada T
    : Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 13: 9–14, 2009
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Miura M,
    2. Fu X,
    3. Zhang QW,
    4. Remick DG,
    5. Fairchild RL
    : Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am J Pathol 159: 2137–2145, 2001
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Cugini D,
    2. Azzollini N,
    3. Gagliardini E,
    4. Cassis P,
    5. Bertini R,
    6. Colotta F,
    7. Noris M,
    8. Remuzzi G,
    9. Benigni A
    : Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 67: 1753–1761, 2005
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Li H,
    2. Nord EP
    : IL-8 amplifies CD40/CD154-mediated ICAM-1 production via the CXCR-1 receptor and p38-MAPK pathway in human renal proximal tubule cells. Am J Physiol Renal Physiol 296: F438–F445, 2009
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Li L,
    2. Huang L,
    3. Sung SS,
    4. Lobo PI,
    5. Brown MG,
    6. Gregg RK,
    7. Engelhard VH,
    8. Okusa MD
    : NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J Immunol 178: 5899–5911, 2007
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Li L,
    2. Huang L,
    3. Vergis AL,
    4. Ye H,
    5. Bajwa A,
    6. Narayan V,
    7. Strieter RM,
    8. Rosin DL,
    9. Okusa MD
    : IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest 120: 331–342, 2010
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Lee JW,
    2. Wang P,
    3. Kattah MG,
    4. Youssef S,
    5. Steinman L,
    6. DeFea K,
    7. Straus DS
    : Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 181: 6536–6545, 2008
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Rabb H
    : Immune modulation of acute kidney injury. J Am Soc Nephrol 17: 604–606, 2006
    OpenUrlFREE Full Text
  33. 33.↵
    1. Fiorina P,
    2. Ansari MJ,
    3. Jurewicz M,
    4. Barry M,
    5. Ricchiuti V,
    6. Smith RN,
    7. Shea S,
    8. Means TK,
    9. Auchincloss H Jr..,
    10. Luster AD,
    11. Sayegh MH,
    12. Abdi R
    : Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol 17: 716–723, 2006
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Sandovici M,
    2. Henning RH,
    3. van Goor H,
    4. Helfrich W,
    5. de Zeeuw D,
    6. Deelman LE
    : Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Kidney Int 73: 1364–1373, 2008
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Gan PY,
    2. Steinmetz OM,
    3. Tan DS,
    4. O'Sullivan KM,
    5. Ooi JD,
    6. Iwakura Y,
    7. Kitching AR,
    8. Holdsworth SR
    : Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol 21: 925–931, 2010
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Furuichi K,
    2. Wada T,
    3. Iwata Y,
    4. Kitagawa K,
    5. Kobayashi K,
    6. Hashimoto H,
    7. Ishiwata Y,
    8. Asano M,
    9. Wang H,
    10. Matsushima K,
    11. Takeya M,
    12. Kuziel WA,
    13. Mukaida N,
    14. Yokoyama H
    : CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 14: 2503–2515, 2003
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Furuichi K,
    2. Gao JL,
    3. Horuk R,
    4. Wada T,
    5. Kaneko S,
    6. Murphy PM
    : Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J Immunol 181: 8670–8676, 2008
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Furuichi K,
    2. Wada T,
    3. Iwata Y,
    4. Kitagawa K,
    5. Kobayashi K,
    6. Hashimoto H,
    7. Ishiwata Y,
    8. Tomosugi N,
    9. Mukaida N,
    10. Matsushima K,
    11. Egashira K,
    12. Yokoyama H
    : Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J Am Soc Nephrol 14: 1066–1071, 2003
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. McIntosh LM,
    2. Barnes JL,
    3. Barnes VL,
    4. McDonald JR
    : Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol 155: 295–303, 2009
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Kinsey GR,
    2. Huang L,
    3. Vergis AL,
    4. Li L,
    5. Okusa MD
    : Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int 77: 771–780, 2010
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Monteiro RM,
    2. Camara NO,
    3. Rodrigues MM,
    4. Tzelepis F,
    5. Damiao MJ,
    6. Cenedeze MA,
    7. Teixeira Vde P,
    8. dos Reis MA,
    9. Pacheco-Silva A
    : A role for regulatory T cells in renal acute kidney injury. Transpl Immunol 21: 50–55, 2009
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Gandolfo MT,
    2. Jang HR,
    3. Bagnasco SM,
    4. Ko GJ,
    5. Agreda P,
    6. Satpute SR,
    7. Crow MT,
    8. King LS,
    9. Rabb H
    : Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int 76: 717–729, 2009
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Kinsey GR,
    2. Sharma R,
    3. Huang L,
    4. Li L,
    5. Vergis AL,
    6. Ye H,
    7. Ju ST,
    8. Oku sa MD
    : Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol 20: 1744–1753, 2009
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Bruhl H,
    2. Cihak J,
    3. Schneider MA,
    4. Plachy J,
    5. Rupp T,
    6. Wenzel I,
    7. Shakarami M,
    8. Milz S,
    9. Ellwart JW,
    10. Stangassinger M,
    11. Schlondorff D,
    12. Mack M
    : Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol 172: 890–898, 2004
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Rice JC,
    2. Spence JS,
    3. Yetman DL,
    4. Safirstein RL
    : Monocyte chemoattractant protein-1 expression correlates with monocyte infiltration in the post-ischemic kidney. Ren Fail 24: 703–723, 2002
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Panzer U,
    2. Kurts C
    : T cell cross-talk with kidney dendritic cells in glomerulonephritis. J Mol Med 88: 19–26, 2010
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Dong X,
    2. Swaminathan S,
    3. Bachman LA,
    4. Croatt AJ,
    5. Nath KA,
    6. Griffin MD
    : Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney. Kidney Int 68: 1096–1108, 2005
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Oh DJ,
    2. Dursun B,
    3. He Z,
    4. Lu L,
    5. Hoke TS,
    6. Ljubanovic D,
    7. Faubel S,
    8. Edelstein CL
    : Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 294: F264–F271, 2008
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Furuichi K,
    2. Gao JL,
    3. Murphy PM
    : Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol 169: 372–387, 2006
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Li L,
    2. Huang L,
    3. Sung SS,
    4. Vergis AL,
    5. Rosin DL,
    6. Rose CE Jr..,
    7. Lobo PI,
    8. Okusa MD
    : The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 74: 1526–1537, 2008
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Segerer S,
    2. Henger A,
    3. Schmid H,
    4. Kretzler M,
    5. Draganovici D,
    6. Brandt U,
    7. Noessner E,
    8. Nelson PJ,
    9. Kerjaschki D,
    10. Schlondorff D,
    11. Regele H
    : Expression of the chemokine receptor CXCR1 in human glomerular diseases. Kidney Int 69: 1765–1773, 2006
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Wada T,
    2. Tomosugi N,
    3. Naito T,
    4. Yokoyama H,
    5. Kobayashi K,
    6. Harada A,
    7. Mukaida N,
    8. Matsushima K
    : Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental acute immune complex-induced glomerulonephritis. J Exp Med 180: 1135–1140, 1994
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Wada T,
    2. Yokoyama H,
    3. Matsushima K,
    4. Kobayashi K
    : Chemokines in renal diseases. Int Immunopharmacol 1: 637–645, 2001
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Yokoyama H,
    2. Wada T,
    3. Furuichi K,
    4. Segawa C,
    5. Shimizu M,
    6. Kobayashi K,
    7. Su S,
    8. Mukaida N,
    9. Matsushima K
    : Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J Leukoc Biol 63: 493–499, 1998
    OpenUrlPubMed
  55. 55.↵
    1. Wada T,
    2. Furuichi K,
    3. Segawa-Takaeda C,
    4. Shimizu M,
    5. Sakai N,
    6. Takeda SI,
    7. Takasawa K,
    8. Kida H,
    9. Kobayashi KI,
    10. Mukaida N,
    11. Ohmoto Y,
    12. Matsushima K,
    13. Yokoyama H
    : MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56: 995–1003, 1999
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Rovin BH,
    2. Rumancik M,
    3. Tan L,
    4. Dickerson J
    : Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 71: 536–542, 1994
    OpenUrlPubMed
  57. 57.↵
    1. Prodjosudjadi W,
    2. Gerritsma JS,
    3. van Es LA,
    4. Daha MR,
    5. Bruijn JA
    : Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis. Clin Nephrol 44: 148–155, 1995
    OpenUrlPubMed
  58. 58.↵
    1. Grandaliano G,
    2. Gesualdo L,
    3. Ranieri E,
    4. Monno R,
    5. Montinaro V,
    6. Marra F,
    7. Schena FP
    : Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: A pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 7: 906–913, 1996
    OpenUrlAbstract
  59. 59.↵
    1. Gesualdo L,
    2. Grandaliano G,
    3. Ranieri E,
    4. Monno R,
    5. Montinaro V,
    6. Manno C,
    7. Schena FP
    : Monocyte recruitment in cryoglobulinemic membranoproliferative glomerulonephritis: A pathogenetic role for monocyte chemotactic peptide-1. Kidney Int 51: 155–163, 1997
    OpenUrlPubMed
  60. 60.↵
    1. Liu ZH,
    2. Chen SF,
    3. Zhou H,
    4. Chen HP,
    5. Li LS
    : Glomerular expression of C-C chemokines in different types of human crescentic glomerulonephritis. Nephrol Dial Transplant 18: 1526–1534, 2003
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Tesch GH
    : MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294: F697–F701, 2008
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Ka SM,
    2. Huang XR,
    3. Lan HY,
    4. Tsai PY,
    5. Yang SM,
    6. Shui HA,
    7. Chen A
    : Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 18: 1777–1788, 2007
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Sato M,
    2. Muragaki Y,
    3. Saika S,
    4. Roberts AB,
    5. Ooshima A
    : Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112: 1486–1494, 2003
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Inazaki K,
    2. Kanamaru Y,
    3. Kojima Y,
    4. Sueyoshi N,
    5. Okumura K,
    6. Kaneko K,
    7. Yamashiro Y,
    8. Ogawa H,
    9. Nakao A
    : Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 66: 597–604, 2004
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Wang W,
    2. Huang XR,
    3. Li AG,
    4. Liu F,
    5. Li JH,
    6. Truong LD,
    7. Wang XJ,
    8. Lan HY
    : Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 16: 1371–1383, 2005
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    1. Schneider A,
    2. Panzer U,
    3. Zahner G,
    4. Wenzel U,
    5. Wolf G,
    6. Thaiss F,
    7. Helmchen U,
    8. Stahl RA
    : Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int 56: 135–144, 1999
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Tang WW,
    2. Qi M,
    3. Warren JS
    : Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 50: 665–671, 1996
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Fujinaka H,
    2. Yamamoto T,
    3. Takeya M,
    4. Feng L,
    5. Kawasaki K,
    6. Yaoita E,
    7. Kondo D,
    8. Wilson CB,
    9. Uchiyama M,
    10. Kihara I
    : Suppression of anti-glomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-1 antibody in WKY rats. J Am Soc Nephrol 8: 1174–1178, 1997
    OpenUrlAbstract
  69. 69.↵
    1. Lloyd CM,
    2. Minto AW,
    3. Dorf ME,
    4. Proudfoot A,
    5. Wells TN,
    6. Salant DJ,
    7. Gutierrez-Ramos JC
    : RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 185: 1371–1380, 1997
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Wenzel U,
    2. Schneider A,
    3. Valente AJ,
    4. Abboud HE,
    5. Thaiss F,
    6. Helmchen UM,
    7. Stahl RA
    : Monocyte chemoattractant protein-1 mediates monocyte/macrophage influx in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int 51: 770–776, 1997
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Panzer U,
    2. Schneider A,
    3. Wilken J,
    4. Thompson DA,
    5. Kent SB,
    6. Stahl RA
    : The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int 56: 2107–2115, 1999
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Wada T,
    2. Furuichi K,
    3. Sakai N,
    4. Iwata Y,
    5. Kitagawa K,
    6. Ishida Y,
    7. Kondo T,
    8. Hashimoto H,
    9. Ishiwata Y,
    10. Mukaida N,
    11. Tomosugi N,
    12. Matsushima K,
    13. Egashira K,
    14. Yokoyama H
    : Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 15: 940–948, 2004
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Shimizu H,
    2. Maruyama S,
    3. Yuzawa Y,
    4. Kato T,
    5. Miki Y,
    6. Suzuki S,
    7. Sato W,
    8. Morita Y,
    9. Maruyama H,
    10. Egashira K,
    11. Matsuo S
    : Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 14: 1496–1505, 2003
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Kanamori H,
    2. Matsubara T,
    3. Mima A,
    4. Sumi E,
    5. Nagai K,
    6. Takahashi T,
    7. Abe H,
    8. Iehara N,
    9. Fukatsu A,
    10. Okamoto H,
    11. Kita T,
    12. Doi T,
    13. Arai H
    : Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360: 772–777, 2007
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Chow FY,
    2. Nikolic-Paterson DJ,
    3. Ozols E,
    4. Atkins RC,
    5. Rollin BJ,
    6. Tesch GH
    : Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69: 73–80, 2006
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Chow FY,
    2. Nikolic-Paterson DJ,
    3. Ma FY,
    4. Ozols E,
    5. Rollins BJ,
    6. Tesch GH
    : Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 50: 471–480, 2007
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Cockwell P,
    2. Chakravorty SJ,
    3. Girdlestone J,
    4. Savage CO
    : Fractalkine expression in human renal inflammation. J Pathol 196: 85–90, 2002
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Koziolek MJ,
    2. Schmid H,
    3. Cohen CD,
    4. Blaschke S,
    5. Hemmerlein B,
    6. Zapf A,
    7. Muller GA,
    8. Strutz F
    : Potential role of fractalkine receptor expression in human renal fibrogenesis. Kidney Int 72: 599–607, 2007
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Yoshimoto S,
    2. Nakatani K,
    3. Iwano M,
    4. Asai O,
    5. Samejima K,
    6. Sakan H,
    7. Terada M,
    8. Harada K,
    9. Akai Y,
    10. Shiiki H,
    11. Nose M,
    12. Saito Y
    : Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis 50: 47–58, 2007
    OpenUrlCrossRefPubMed
  80. 80.↵
    1. Koziolek MJ,
    2. Muller GA,
    3. Zapf A,
    4. Patschan D,
    5. Schmid H,
    6. Cohen CD,
    7. Koschnick S,
    8. Vasko R,
    9. Bramlage C,
    10. Strutz F
    : Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure. Nephrol Dial Transplant 25: 684–698, 2010
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Katsuyama K,
    2. Fujinaka H,
    3. Yamamoto K,
    4. Nameta M,
    5. Yaoita E,
    6. Yoshida Y,
    7. Tomizawa S,
    8. Uchiyama M,
    9. Yamamoto T
    : Expression of the chemokine fractalkine (FKN/CX3CL1) by podocytes in normal and proteinuric rat kidney glomerulus. Nephron Exp Nephrol 113: e45–e56, 2009
    OpenUrlPubMed
  82. 82.↵
    1. Kikuchi Y,
    2. Ikee R,
    3. Hemmi N,
    4. Hyodo N,
    5. Saigusa T,
    6. Namikoshi T,
    7. Yamada M,
    8. Suzuki S,
    9. Miura S
    : Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron Exp Nephrol 97: e17–e25, 2004
    OpenUrlCrossRefPubMed
  83. 83.↵
    1. Durkan AM,
    2. Alexander RT,
    3. Liu GY,
    4. Rui M,
    5. Femia G,
    6. Robinson LA
    : Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells. J Am Soc Nephrol 18: 74–83, 2007
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    1. Feng L,
    2. Chen S,
    3. Garcia GE,
    4. Xia Y,
    5. Siani MA,
    6. Botti P,
    7. Wilson CB,
    8. Harrison JK,
    9. Bacon KB
    : Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int 56: 612–620, 1999
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. Turner JE,
    2. Paust HJ,
    3. Steinmetz OM,
    4. Panzer U
    : The Th17 immune response in renal inflammation. Kidney Int 77: 1070–1075, 2010
    OpenUrlCrossRefPubMed
  86. 86.↵
    1. Tipping PG,
    2. Holdsworth SR
    : T cells in crescentic glomerulonephritis. J Am Soc Nephrol 17: 1253–1263, 2006
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. Furuichi K,
    2. Wada T,
    3. Sakai N,
    4. Iwata Y,
    5. Yoshimoto K,
    6. Shimizu M,
    7. Kobayashi K,
    8. Takasawa K,
    9. Kida H,
    10. Takeda SI,
    11. Mukaida N,
    12. Matsushima K,
    13. Yokoyama H
    : Distinct expression of CCR1 and CCR5 in glomerular and interstitial lesions of human glomerular diseases. Am J Nephrol 20: 291–299, 2000
    OpenUrlCrossRefPubMed
  88. 88.↵
    1. Turner JE,
    2. Paust HJ,
    3. Steinmetz OM,
    4. Peters A,
    5. Meyer-Schwesinger C,
    6. Heymann F,
    7. Helmchen U,
    8. Fehr S,
    9. Horuk R,
    10. Wenzel U,
    11. Kurts C,
    12. Mittrucker HW,
    13. Stahl RA,
    14. Panzer U
    : CCR5 deficiency aggravates crescentic glomerulonephritis in mice. J Immunol 181: 6546–6556, 2008
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Phoon RK,
    2. Kitching AR,
    3. Odobasic D,
    4. Jones LK,
    5. Semple TJ,
    6. Holdsworth SR
    : T-bet deficiency attenuates renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 19: 477–485, 2008
    OpenUrlAbstract/FREE Full Text
  90. 90.↵
    1. Enghard P,
    2. Humrich JY,
    3. Rudolph B,
    4. Rosenberger S,
    5. Biesen R,
    6. Kuhn A,
    7. Manz R,
    8. Hiepe F,
    9. Radbruch A,
    10. Burmester GR,
    11. Riemekasten G
    : CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum 60: 199–206, 2009
    OpenUrlCrossRefPubMed
  91. 91.↵
    1. Perez de Lema G,
    2. Maier H,
    3. Nieto E,
    4. Vielhauer V,
    5. Luckow B,
    6. Mampaso F,
    7. Schlondorff D
    : Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 12: 1369–1382, 2001
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    1. Han GD,
    2. Koike H,
    3. Nakatsue T,
    4. Suzuki K,
    5. Yoneyama H,
    6. Narumi S,
    7. Kobayashi N,
    8. Mundel P,
    9. Shimizu F,
    10. Kawachi H
    : IFN-inducible protein-10 has a differential role in podocyte during Thy 1.1 glomerulonephritis. J Am Soc Nephrol 14: 3111–3126, 2003
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    1. Steinmetz OM,
    2. Turner JE,
    3. Paust HJ,
    4. Lindner M,
    5. Peters A,
    6. Heiss K,
    7. Velden J,
    8. Hopfer H,
    9. Fehr S,
    10. Krieger T,
    11. Meyer-Schwesinger C,
    12. Meyer TN,
    13. Helmchen U,
    14. Mittrucker HW,
    15. Stahl RA,
    16. Panzer U
    : CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J Immunol 183: 4693–4704, 2009
    OpenUrlAbstract/FREE Full Text
  94. 94.↵
    1. Panzer U,
    2. Steinmetz OM,
    3. Paust HJ,
    4. Meyer-Schwesinger C,
    5. Peters A,
    6. Turner JE,
    7. Zahner G,
    8. Heymann F,
    9. Kurts C,
    10. Hopfer H,
    11. Helmchen U,
    12. Haag F,
    13. Schneider A,
    14. Stahl RA
    : Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J Am Soc Nephrol 18: 2071–2084, 2007
    OpenUrlAbstract/FREE Full Text
  95. 95.↵
    1. Mahajan D,
    2. Wang Y,
    3. Qin X,
    4. Zheng G,
    5. Wang YM,
    6. Alexander SI,
    7. Harris DC
    : CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol 17: 2731–2741, 2006
    OpenUrlAbstract/FREE Full Text
  96. 96.↵
    1. Wolf D,
    2. Hochegger K,
    3. Wolf AM,
    4. Rumpold HF,
    5. Gastl G,
    6. Tilg H,
    7. Mayer G,
    8. Gunsilius E,
    9. Rosenkranz AR
    : CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol 16: 1360–1370, 2005
    OpenUrlAbstract/FREE Full Text
  97. 97.↵
    1. Wang YM,
    2. Zhang GY,
    3. Wang Y,
    4. Hu M,
    5. Wu H,
    6. Watson D,
    7. Hori S,
    8. Alexander IE,
    9. Harris DC,
    10. Alexander SI
    : Foxp3-transduced polyclonal regulatory T cells protect against chronic renal injury from adriamycin. J Am Soc Nephrol 17: 697–706, 2006
    OpenUrlAbstract/FREE Full Text
  98. 98.↵
    1. Davalos-Misslitz AC,
    2. Rieckenberg J,
    3. Willenzon S,
    4. Worbs T,
    5. Kremmer E,
    6. Bernhardt G,
    7. Forster R
    : Generalized multi-organ autoimmunity in CCR7-deficient mice. Eur J Immunol 37: 613–622, 2007
    OpenUrlCrossRefPubMed
  99. 99.↵
    1. Schneider MA,
    2. Meingassner JG,
    3. Lipp M,
    4. Moore HD,
    5. Rot A
    : CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 204: 735–745, 2007
    OpenUrlAbstract/FREE Full Text
  100. 100.↵
    1. Eller K,
    2. Weber T,
    3. Pruenster M,
    4. Wolf AM,
    5. Mayer G,
    6. Rosenkranz AR,
    7. Rot A
    : CCR7 deficiency exacerbates injury in acute nephritis due to aberrant localization of regulatory T cells. J Am Soc Nephrol 21: 42–52, 2010
    OpenUrlAbstract/FREE Full Text
  101. 101.↵
    1. Turner JE,
    2. Paust HJ,
    3. Steinmetz OM,
    4. Peters A,
    5. Riedel JH,
    6. Erhardt A,
    7. Wegscheid C,
    8. Velden J,
    9. Fehr S,
    10. Mittrucker HW,
    11. Tiegs G,
    12. Stahl RA,
    13. Panzer U
    : CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis. J Am Soc Nephrol 21: 974–985, 2010
    OpenUrlAbstract/FREE Full Text
  102. 102.↵
    1. Strom TB,
    2. Koulmanda M
    : Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol 20: 1677–1680, 2009
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 22 (5)
Journal of the American Society of Nephrology
Vol. 22, Issue 5
1 May 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Chemokines in Renal Injury
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Chemokines in Renal Injury
Arthur C. K. Chung, Hui Y. Lan
JASN May 2011, 22 (5) 802-809; DOI: 10.1681/ASN.2010050510

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Chemokines in Renal Injury
Arthur C. K. Chung, Hui Y. Lan
JASN May 2011, 22 (5) 802-809; DOI: 10.1681/ASN.2010050510
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • CHEMOKINES AND CHEMOKINE RECEPTORS
    • REGULATION OF CHEMOKINE EXPRESSION
    • ROLE OF CHEMOKINES IN ACUTE KIDNEY INJURY
    • ROLE OF CHEMOKINES IN CHRONIC KIDNEY DISEASES
    • CONCLUSION
    • DISCLOSURES
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Collaboration between Dialysis Providers
  • Unfulfilled Expectations Open New Horizons: What Have We Learned about Volume-Regulated Anion Channels in the Kidney?
  • Polycystin-2 in the Endoplasmic Reticulum: Bending Ideas about the Role of the Cilium
Show more Up Front Matters

Brief Reviews

  • Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach
  • Salt-Losing Tubulopathies in Children: What’s New, What’s Controversial?
  • Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives
Show more Brief Reviews

Cited By...

  • Acute Kidney Injury Instigates Malignant Renal Cell Carcinoma via CXCR2 in Mice with Inactivated Trp53 and Pten in Proximal Tubular Kidney Epithelial Cells
  • Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression
  • Advantages of Single-Nucleus over Single-Cell RNA Sequencing of Adult Kidney: Rare Cell Types and Novel Cell States Revealed in Fibrosis
  • Endogenous IL-33 Contributes to Kidney Ischemia-Reperfusion Injury as an Alarmin
  • Reducing Inflammatory Cytokine Production from Renal Collecting Duct Cells by Inhibiting GATA2 Ameliorates Acute Kidney Injury
  • Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD
  • Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage
  • Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental Lupus
  • Chronically Elevated Levels of Short-Chain Fatty Acids Induce T Cell-Mediated Ureteritis and Hydronephrosis
  • CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN
  • SIRT2 Regulates LPS-Induced Renal Tubular CXCL2 and CCL2 Expression
  • Epiretinal Membrane Inflammatory Cell Density Might Reflect the Activity of Proliferative Diabetic Retinopathy
  • Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation
  • CXCR6 Plays a Critical Role in Angiotensin II-Induced Renal Injury and Fibrosis
  • Beyond Tissue Injury--Damage-Associated Molecular Patterns, Toll-Like Receptors, and Inflammasomes Also Drive Regeneration and Fibrosis
  • Critical Role of CXCL16 in Hypertensive Kidney Injury and Fibrosis
  • Dragon (Repulsive Guidance Molecule RGMb) Inhibits E-cadherin Expression and Induces Apoptosis in Renal Tubular Epithelial Cells
  • Messengers without Borders: Mediators of Systemic Inflammatory Response in AKI
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire